NGEN (NervGen Pharma) OCF Margin %: 0.00% (As of Mar. 2026)


NGEN NervGen Pharma Corp NGEN
22 GF Score
Price $1.87
! 2 Warning Signs
View Full Analysis

What is NervGen Pharma OCF Margin %?

NervGen Pharma NGEN -1.06% 22 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates NGEN with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, NervGen Pharma ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. NervGen Pharma's Cash Flow from Operations for the three months ended in Mar. 2026 was $0.00 Mil. NervGen Pharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, NervGen Pharma's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, NervGen Pharma's current OCF Yield % is -4.78%.

The historical rank and industry rank for NervGen Pharma's OCF Margin % or its related term are showing as below:


NGEN's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

NervGen Pharma OCF Margin % Related Terms

NervGen Pharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for NervGen Pharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma OCF Margin % Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

NervGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NGEN
22GF Score
NervGen Pharma Corp NGEN
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NervGen Pharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

NervGen Pharma's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-14.135/0
= %

NervGen Pharma's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
NervGen Pharma (NGEN) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on NervGen Pharma and its competitors. According to the industry distribution chart, NervGen Pharma ranks #999999 out of 959 companies in the Biotechnology industry.
Is NervGen Pharma's OCF Margin % too high?
NervGen Pharma's current OCF Margin % is 0.00%. Based on the distribution chart, NervGen Pharma ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NervGen Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's OCF Margin % compare to CNTN and ELTX?
According to the Biotechnology industry distribution chart, NervGen Pharma ranks #999999 out of 959 companies for OCF Margin %. This places NervGen Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on NervGen Pharma and its competitors. NervGen Pharma's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (NGEN) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. NervGen Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For NervGen Pharma (NGEN), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NervGen Pharma Business Description

Other Exchanges 9UA:Germany
Address 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score

Get the complete analysis for NGEN

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.87
Price